Correction to: Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists

Drug Saf. 2019 Jul;42(7):919. doi: 10.1007/s40264-019-00830-5.

Abstract

In the original publication of this article, the following correction should be noted in Table 1.

Publication types

  • Published Erratum